KEYNOTE-564 is the first trial to demonstrate an overall survival benefit with adjuvant immunotherapy in patients with clear cell renal cell carcinoma.
Welireg outperformed Afinitor in time to disease progression and patient-reported quality of life in the treatment of metastatic clear cell renal cell carcinoma.